Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Financial Statements
- Click here to download Vertex Pharmaceuticals, Inc.'s Income Statement
- Click here to download Vertex Pharmaceuticals, Inc.'s Balance Sheet
- Click here to download Vertex Pharmaceuticals, Inc.'s Statement of Cash Flows
Key Info
- Industry: Pharmaceutical Preparation Manufacturing
- Sector: Manufacturing
- CEO Name: Jeffrey Leiden
Key Statistics
- Stock Price: $181.39
- Dividend Yield: 0%
- Market Capitalization: $47,273,041,955
- Shares Outstanding: 259,428,394
- Number of Employees: 3,400
- Trailing 12-Month EPS: $7.59
- Trailing 12-Month DPS: $0
- Payout Ratio: 0.0%
Important Dates
- Next Earnings Date: 2021-10-28
- Next Ex-Dividend Date:
Price Trends
- Current Stock Price: $181.39
- 52-week high: $280.99
- 52-week low: $180.02
- 200-day moving average: $203.54
- 50-day moving average: $192.1
Performance
- 1-Month Price Return: -8.9%
- 3-Month Price Return: -7.4%
- 6-Month Price Return: -15.9%
- 1-Year Price Return: -32.6%
- 2-Year Price Return: 9.3%
- 5-Year Price Return: 114.4%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast